Scarica l'app Stockscreener
2.41
0.62%
-0.015
Pavmed Inc Borsa (PAVM) Ultime notizie
PAVmed Launches New At-the-Market Equity Offering - The Globe and Mail
PAVmed Launches New At-the-Market Equity Offering - TipRanks
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Q1 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Inc. Series Z Warrant (PAVMZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
PAVmed Inc (PAVMW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Completion of Louisville VA Medical Center delayed until 2027 - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the ClosePost-Earnings Reaction - vinanet.vn
WVU PCH updates their signage and navigation - AOL.com
VA touts psilocybin trial for vets, but relief could take time - AOL.com
Verasonics Appoints New Senior Vice President, Research & Development - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the CloseInvestor Earnings Call - dars.gov.et
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfitability Analysis - vinanet.vn
Former President of DePuy Synthes U.S. Joins Peptilogics Board - AOL.com
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfit Guidance Range - dars.gov.et
PAVmed Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-08-17 - Seeking Alpha
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVM Q1 2026 Earnings: EPS of -$4.42 Misses Consensus by 519%; Shares Rally 9.7%ROA Comparison - vinanet.vn
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com India
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Canada
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Canada
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
10.41%
7.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):